TY - JOUR
T1 - Prophylactic use of alpha-1 adrenergic blocking agents for prevention of postoperative urinary retention: A review & meta-analysis of randomized clinical trials
AU - Ghuman, Amandeep
AU - de Jonge, S. W.
AU - Dryden, Simon D.
AU - Feeney, Timothy
AU - Buitrago, Daniel H.
AU - Phang, P. Terry
PY - 2018
Y1 - 2018
N2 - Background: Alpha-1 adrenergic blockers used to treat postoperative urinary retention (POUR) may also have a preventative role. Here we assess the evidence behind their prophylactic use on POUR prevention. Study design: PRISMA guidelines were followed. All studies reviewed for eligibility, data extraction, and risk of bias assessment. Pooled risk ratios with 95% confidence intervals calculated using a random effects model. Heterogeneity assessed using Forest plots, I2 statistic and Chi-squared Cochran's Q-statistic. Results: Fifteen RCTs (1732 patients) included. Prophylactic alpha-1 adrenergic blockers significantly reduced risk of POUR, 13.16% vs 30.24%, RR = 0.48 (95%CI: 0.33; 0.70, p-value =.001), without a statistically significant increase in adverse events. Substantial heterogeneity found between included studies (I2 = 65.49% [95%CI:48.49; 95.01] & Q-statistic 43.46 (p-value<.001)). Subgroup analysis revealed strong risk reduction and little heterogeneity in males (RR:0.33, 95%CI:0.23; 0.47, p-value<.001, I2:10.58) and patients receiving spinal anesthesia (RR:0.26, 95%CI:0.14; 0.46, p-value<.0001, I2 = 0%). Conclusion: Prophylactic alpha-1 adrenergic blockers reduce risk of POUR in males and after spinal anesthesia.
AB - Background: Alpha-1 adrenergic blockers used to treat postoperative urinary retention (POUR) may also have a preventative role. Here we assess the evidence behind their prophylactic use on POUR prevention. Study design: PRISMA guidelines were followed. All studies reviewed for eligibility, data extraction, and risk of bias assessment. Pooled risk ratios with 95% confidence intervals calculated using a random effects model. Heterogeneity assessed using Forest plots, I2 statistic and Chi-squared Cochran's Q-statistic. Results: Fifteen RCTs (1732 patients) included. Prophylactic alpha-1 adrenergic blockers significantly reduced risk of POUR, 13.16% vs 30.24%, RR = 0.48 (95%CI: 0.33; 0.70, p-value =.001), without a statistically significant increase in adverse events. Substantial heterogeneity found between included studies (I2 = 65.49% [95%CI:48.49; 95.01] & Q-statistic 43.46 (p-value<.001)). Subgroup analysis revealed strong risk reduction and little heterogeneity in males (RR:0.33, 95%CI:0.23; 0.47, p-value<.001, I2:10.58) and patients receiving spinal anesthesia (RR:0.26, 95%CI:0.14; 0.46, p-value<.0001, I2 = 0%). Conclusion: Prophylactic alpha-1 adrenergic blockers reduce risk of POUR in males and after spinal anesthesia.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85041615713&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29397894
U2 - https://doi.org/10.1016/j.amjsurg.2018.01.015
DO - https://doi.org/10.1016/j.amjsurg.2018.01.015
M3 - Review article
C2 - 29397894
SN - 0002-9610
VL - 215
SP - 973
EP - 979
JO - American Journal of Surgery
JF - American Journal of Surgery
IS - 5
ER -